162 related articles for article (PubMed ID: 11249711)
1. AG-7088 Pfizer.
Witherell G
Curr Opin Investig Drugs; 2000 Nov; 1(3):297-302. PubMed ID: 11249711
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
Dragovich PS; Prins TJ; Zhou R; Webber SE; Marakovits JT; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Ford CE; Burke BJ; Rejto PA; Hendrickson TF; Tuntland T; Brown EL; Meador JW; Ferre RA; Harr JE; Kosa MB; Worland ST
J Med Chem; 1999 Apr; 42(7):1213-24. PubMed ID: 10197965
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.
Dragovich PS; Prins TJ; Zhou R; Fuhrman SA; Patick AK; Matthews DA; Ford CE; Meador JW; Ferre RA; Worland ST
J Med Chem; 1999 Apr; 42(7):1203-12. PubMed ID: 10197964
[TBL] [Abstract][Full Text] [Related]
4. Valdecoxib (Pharmacia).
Gotta AW
Curr Opin Investig Drugs; 2002 Feb; 3(2):240-5. PubMed ID: 12020053
[TBL] [Abstract][Full Text] [Related]
5. Development of potent inhibitors of the coxsackievirus 3C protease.
Lee ES; Lee WG; Yun SH; Rho SH; Im I; Yang ST; Sellamuthu S; Lee YJ; Kwon SJ; Park OK; Jeon ES; Park WJ; Kim YC
Biochem Biophys Res Commun; 2007 Jun; 358(1):7-11. PubMed ID: 17485072
[TBL] [Abstract][Full Text] [Related]
6. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.
Binford SL; Maldonado F; Brothers MA; Weady PT; Zalman LS; Meador JW; Matthews DA; Patick AK
Antimicrob Agents Chemother; 2005 Feb; 49(2):619-26. PubMed ID: 15673742
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.
Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Reich SH; Marakovits JT; Prins TJ; Zhou R; Tikhe J; Littlefield ES; Bleckman TM; Wallace MB; Little TL; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; DeLisle DM; Worland ST
J Med Chem; 1998 Jul; 41(15):2819-34. PubMed ID: 9667971
[TBL] [Abstract][Full Text] [Related]
8. Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.
Webber SE; Okano K; Little TL; Reich SH; Xin Y; Fuhrman SA; Matthews DA; Love RA; Hendrickson TF; Patick AK; Meador JW; Ferre RA; Brown EL; Ford CE; Binford SL; Worland ST
J Med Chem; 1998 Jul; 41(15):2786-805. PubMed ID: 9667969
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.
Dragovich PS; Prins TJ; Zhou R; Johnson TO; Hua Y; Luu HT; Sakata SK; Brown EL; Maldonado FC; Tuntland T; Lee CA; Fuhrman SA; Zalman LS; Patick AK; Matthews DA; Wu EY; Guo M; Borer BC; Nayyar NK; Moran T; Chen L; Rejto PA; Rose PW; Guzman MC; Dovalsantos EZ; Lee S; McGee K; Mohajeri M; Liese A; Tao J; Kosa MB; Liu B; Batugo MR; Gleeson JP; Wu ZP; Liu J; Meador JW; Ferre RA
J Med Chem; 2003 Oct; 46(21):4572-85. PubMed ID: 14521419
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Reich SH; Prins TJ; Marakovits JT; Littlefield ES; Zhou R; Tikhe J; Ford CE; Wallace MB; Meador JW; Ferre RA; Brown EL; Binford SL; Harr JE; DeLisle DM; Worland ST
J Med Chem; 1998 Jul; 41(15):2806-18. PubMed ID: 9667970
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.
Webber SE; Tikhe J; Worland ST; Fuhrman SA; Hendrickson TF; Matthews DA; Love RA; Patick AK; Meador JW; Ferre RA; Brown EL; DeLisle DM; Ford CE; Binford SL
J Med Chem; 1996 Dec; 39(26):5072-82. PubMed ID: 8978838
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication.
Kong JS; Venkatraman S; Furness K; Nimkar S; Shepherd TA; Wang QM; Aubé J; Hanzlik RP
J Med Chem; 1998 Jul; 41(14):2579-87. PubMed ID: 9651162
[TBL] [Abstract][Full Text] [Related]
13. New anti-viral drugs for the treatment of the common cold.
Maugeri C; Alisi MA; Apicella C; Cellai L; Dragone P; Fioravanzo E; Florio S; Furlotti G; Mangano G; Ombrato R; Luisi R; Pompei R; Rincicotti V; Russo V; Vitiello M; Cazzolla N
Bioorg Med Chem; 2008 Mar; 16(6):3091-107. PubMed ID: 18248816
[TBL] [Abstract][Full Text] [Related]
14. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.
Matthews DA; Dragovich PS; Webber SE; Fuhrman SA; Patick AK; Zalman LS; Hendrickson TF; Love RA; Prins TJ; Marakovits JT; Zhou R; Tikhe J; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; Brothers MA; DeLisle DM; Worland ST
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11000-7. PubMed ID: 10500114
[TBL] [Abstract][Full Text] [Related]
15. Pleconaril Sanofi Synthélabo/ViroPharma.
Billich A
Curr Opin Investig Drugs; 2000 Nov; 1(3):303-7. PubMed ID: 11249712
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.
Dragovich PS; Prins TJ; Zhou R; Brown EL; Maldonado FC; Fuhrman SA; Zalman LS; Tuntland T; Lee CA; Patick AK; Matthews DA; Hendrickson TF; Kosa MB; Liu B; Batugo MR; Gleeson JP; Sakata SK; Chen L; Guzman MC; Meador JW; Ferre RA; Worland ST
J Med Chem; 2002 Apr; 45(8):1607-23. PubMed ID: 11931615
[TBL] [Abstract][Full Text] [Related]
17. Cariporide Aventis.
Chin B; Lip GY
Curr Opin Investig Drugs; 2000 Nov; 1(3):340-6. PubMed ID: 11249717
[TBL] [Abstract][Full Text] [Related]
18. Quantitative structure-activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives. Inhibitors of human rhinovirus 2 replication.
Kuz'min VE; Artemenko AG; Muratov EN; Volineckaya IL; Makarov VA; Riabova OB; Wutzler P; Schmidtke M
J Med Chem; 2007 Aug; 50(17):4205-13. PubMed ID: 17665898
[TBL] [Abstract][Full Text] [Related]
19. Non-covalent inhibitors of rhinovirus 3C protease.
Baxter A; Chambers M; Edfeldt F; Edman K; Freeman A; Johansson C; King S; Morley A; Petersen J; Rawlins P; Spadola L; Thong B; Van de Poël H; Williams N
Bioorg Med Chem Lett; 2011 Jan; 21(2):777-80. PubMed ID: 21183345
[TBL] [Abstract][Full Text] [Related]
20. In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.
Binford SL; Weady PT; Maldonado F; Brothers MA; Matthews DA; Patick AK
Antimicrob Agents Chemother; 2007 Dec; 51(12):4366-73. PubMed ID: 17908951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]